SPOTLIGHT -
Dr. McCollum on the Clinical Utility of Regorafenib in mCRC
A. David McCollum, MD, attending oncologist, Baylor University Medical Center, discusses the clinical utility of regorafenib (Stivarga) in metastatic colorectal cancer (mCRC).
Read More
Dr. McCollum on Maintenance Therapy for Metastatic CRC
A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses maintenance therapy for patients with metastatic colorectal cancer.
Dr. McCollum on Molecular Testing in CRC
A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses molecular testing in patients with colorectal cancer (CRC).
Dr. McCollum on Frontline Therapy for Patients With Metastatic CRC
A. David McCollum, MD, oncologist, Baylor University Medical Center, discusses frontline therapy for patients with metastatic colorectal cancer (mCRC).
Dr. McCollum Discusses Immunotherapy in CRC
A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses integrating immunotherapy into the treatment landscape of colorectal cancer (CRC).
Dr. McCollum on Drug Sequences for Patients With CRC
A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses drug sequences for patients with colorectal cancer (CRC).
Dr. McCollum on Treatment in the First-Line Setting for CRC
A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
